Cargando…
ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies
SIMPLE SUMMARY: A considerable number of estrogen-receptor–positive (ER+) breast cancer patients develop resistance to endocrine treatment. One of the most important resistance mechanisms is the presence of ESR1 mutations. In the present study, we developed and analytically validated a novel, highly...
Autores principales: | Stergiopoulou, Dimitra, Markou, Athina, Tzanikou, Eleni, Ladas, Ioannis, Makrigiorgos, G. Mike, Georgoulias, Vassilis, Lianidou, Evi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867152/ https://www.ncbi.nlm.nih.gov/pubmed/33535614 http://dx.doi.org/10.3390/cancers13030556 |
Ejemplares similares
-
Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023) -
Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
por: Stergiopoulou, Dimitra, et al.
Publicado: (2022) -
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019) -
PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
por: Markou, Athina, et al.
Publicado: (2020) -
ESR1 and ESR2 genotypes and the age at menarche in idiopathic scoliosis
por: Janusz, Piotr, et al.
Publicado: (2014)